Oriol Mirallas MD (@DrMirallas) ranks #16 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: WU-KONG28, PROTEUS, RASolute 302. This profile quotes their 19 trial posts from 2026 word for word, with links to the originals on X.
At a Glance
- 19 posts naming a trial in 2026
- 16 trials discussed by name
- Lung Cancer: US #16, Global #39 · 14 physicians engaged
- Leading physician voice: #2 of 5 physicians on CheckMate-77T
This Month
What Oriol Mirallas MD has posted in the last 30 days. Updated November 10, 2026.
📣 Second Presidential Symposium #ESMO26 👉🏽 SAFFRON: Osimertinib + Savolitinib vs Platinum-Pemetrexed #EGFR #MET # NSCLC 📌 PFS 7.6 vs 5.4m HR 0.55 📌 OS 17.8 vs 12.9m HR 0.68 ☣️ 64% grade 3 or higher, OST frequent GI and hematologic @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
📣 Second Presidential Symposium #ESMO26 👉🏽 CLARITY-Gastric 01 (CG-01): phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2)-positive gastroesophageal carcinoma (GEC) 🗣️ Discussed by @salahAlBatran 📌 PFS 4.1 vs 2.7m HR 0.56 (3+L) 📌 OS 10 vs 5m HR 0.47 (3+L) ☣️ Most frequent GI, decreased appetite and hematologic ☣️ Grade 3 or higher 36.4% @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
📣 Second Presidential Symposium #ESMO26 👉🏽 Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1) 🗣️ Dr. Zhou 📌 PFS 8.4 vs 5.8m HR 0.61 📌 OS 14.9 vs 12.1m HR 0.75 ☣️ Most frequent hematologic, AST elevation, proteinuria ☣️ Grade 3 or higher 82 vs 72% @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
📣 Second Presidential Symposium #ESMO26 KRASCENDO-1: Divarasib vs Sotorasib/Adagrasib in 1-3L #KRASG12C #NSCLC 📌 PFS 9.8 vs 5.7m HR 0.58 📌 OS 17.7 vs 12m HR 0.56 ☣️ Diarrhea (66%), N/V (53/39%) @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽 https://t.co/M21g3ISLPv
🔥 Presidential Symposium I #ESMO26 🗣️ @sands_jacob @DanaFarber DeLLphi-305 trial evaluating tarlatamab + durva vs durva as 1LM therapy for ES-SCLC. ✔️ mOS 21.1 vs 12.7m HR 0.42 ✔️ mPFS 7.4 vs 1.9m HR 0.34 ✔️ ORR 26.4 vs 4.1% ☣️ 46.8 vs 40.6% grade 3 or higher @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
🔥 Presidential Symposium I #ESMO26 🗣️ @tompowles1 👉🏽 VOLGA phase 3, randomised, open-label trial, enrolled pts with MIBC (cT2-T4aN0/1M0 or cT1N1M0) ineligible for or refused cisplatin and were planned for RC 📌 EFS D+EV vs control: NR vs 12.1 HR 0.51 D+T+EV: NR (HR 0.61) 📌 OS D+EV vs control: 78 VS 69% at 24m HR 0.58 Triplet vs control: NS 📌 pCR Doublet vs control: 45 vs 8% 🩸ctDNA clearance impacts survival @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @brunolarvol 👇🏽👇🏽
Who Amplifies Oriol Mirallas MD
Physicians who reposted Oriol Mirallas MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #16 | #39 | 14 | 20 | Full ranking |
Trials Oriol Mirallas MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| WU-KONG28 | 3 | #15 of 29 | May 29, 2026 |
| PROTEUS | 2 | #41 of 56 | Jun 1, 2026 |
| RASolute 302 | 2 | #24 of 73 | Jun 1, 2026 |
| SAFFRON | 1 | #16 of 50 | Oct 25, 2026 |
| CLARITY-Gastric01 (CG-01) | 1 | #17 of 26 | Oct 25, 2026 |
| HARMONi-GI1 (AK112-309) | 1 | #22 of 26 | Oct 25, 2026 |
| KRASCENDO-1 | 1 | #30 of 49 | Oct 25, 2026 |
| DeLLphi-305 | 1 | #42 of 86 | Oct 24, 2026 |
| VOLGA | 1 | #31 of 57 | Oct 24, 2026 |
| HARMONi-6 | 1 | #20 of 74 | May 31, 2026 |
| LIBRETTO-432 | 1 | #27 of 53 | May 31, 2026 |
| OptiTROP-Lung05 | 1 | #9 of 19 | May 29, 2026 |
| CHRYSALIS-2 | 1 | #10 of 14 | May 29, 2026 |
| CROWN | 1 | #30 of 36 | May 29, 2026 |
| IMvigor011 | 1 | #14 of 20 | Apr 19, 2026 |
| CheckMate-77T | 1 | #2 of 5 | Apr 18, 2026 |
Oriol Mirallas MD on WU-KONG28
#ASCO26 🫁 Lung Cancer Oral Track 💥 WU-KONG28 Phase III Trial: 🗣️ Dr. Hey mach @UTMDAnderson 🎯 Sunvozertinib versus platinum-based chemotherapy as 1L NSCLC with EGFR exon20ins ✅ PFS 10.3 vs 7.5m ✅ PFS2 21.7m vs 15.5m ✅ ORR 59 vs 31% ✅ DOR 11.2 vs 7.1m ☣️ Toxicity: https://t.co/NFillJP5aF
#ASCO26 🫁 Lung Cancer Oral Track 💥 WU-KONG28 Phase III Trial: 🗣️ Dr. Ramakant ⚡🧠 Wait or treat? Managing asymptomatic brain metastases in #EGFR #ALK NSCLC RT upfront vs delayed RT: ✅ Intracranial 🧠PD 21.7 vs 50% (HR 0.35!) ❌ Intracranial PFS 18.2 vs 14.8m ❌ Overall https://t.co/MmqvIa9YSZ
#ASCO26 🫁 Lung Cancer Oral Track 💥 WU-KONG28 Phase III Trial: 🗣️ Dr. Ramakant ⚡🧠 Wait or treat? Managing asymptomatic brain metastases in #EGFR #ALK NSCLC RT upfront vs delayed RT: ✅ Intracranial 🧠PD 21.7 vs 50% (HR 0.35!) ✅ Delayed arm had more change to receive https://t.co/JXB6mhIOkh
Oriol Mirallas MD on PROTEUS
🤩 What a tremendous Day 3 #ASCO26 @ONCOALERT RoundUp🚨 🔹 #RASolute302: Daraxonrasib first RAS-targeted therapy to improve OS in 2L #PDAC (13.2 vs 6.6 mo) 🔹 #LIBRETTO: Adjuvant selpercatinib cut PD risk by 83% in RET+ sII-III NSCLC 🔹 #PROTEUS: Perioperative apalutamide https://t.co/ehIApvnuG0
#ASCO26 💥 Plenary Sessions 5-practice changing studies🤯 1. PROTEUS: Phase 3 of Perioperative (neoadjuvant and adjuvant) apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC) ✅ pCR/MRD 9 vs 1% https://t.co/UGiORNXisZ
Oriol Mirallas MD on RASolute 302
🤩 What a tremendous Day 3 #ASCO26 @ONCOALERT RoundUp🚨 🔹 #RASolute302: Daraxonrasib first RAS-targeted therapy to improve OS in 2L #PDAC (13.2 vs 6.6 mo) 🔹 #LIBRETTO: Adjuvant selpercatinib cut PD risk by 83% in RET+ sII-III NSCLC 🔹 #PROTEUS: Perioperative apalutamide https://t.co/ehIApvnuG0
#ASCO26 💥 Plenary Sessions THE most expected #KRAS @RevMedicines 5. RASolute 302: Phase 3 of Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC) 🗣️ Dr. Wilson @DanaFarber ✅ mOS 13.2 vs 6.7m, https://t.co/yoGeU1NJXi
Oriol Mirallas MD on SAFFRON
📣 Second Presidential Symposium #ESMO26 👉🏽 SAFFRON: Osimertinib + Savolitinib vs Platinum-Pemetrexed #EGFR #MET # NSCLC 📌 PFS 7.6 vs 5.4m HR 0.55 📌 OS 17.8 vs 12.9m HR 0.68 ☣️ 64% grade 3 or higher, OST frequent GI and hematologic @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
Oriol Mirallas MD on CLARITY-Gastric01 (CG-01)
📣 Second Presidential Symposium #ESMO26 👉🏽 CLARITY-Gastric 01 (CG-01): phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2)-positive gastroesophageal carcinoma (GEC) 🗣️ Discussed by @salahAlBatran 📌 PFS 4.1 vs 2.7m HR 0.56 (3+L) 📌 OS 10 vs 5m HR 0.47 (3+L) ☣️ Most frequent GI, decreased appetite and hematologic ☣️ Grade 3 or higher 36.4% @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
Oriol Mirallas MD on HARMONi-GI1 (AK112-309)
📣 Second Presidential Symposium #ESMO26 👉🏽 Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1) 🗣️ Dr. Zhou 📌 PFS 8.4 vs 5.8m HR 0.61 📌 OS 14.9 vs 12.1m HR 0.75 ☣️ Most frequent hematologic, AST elevation, proteinuria ☣️ Grade 3 or higher 82 vs 72% @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
Oriol Mirallas MD on KRASCENDO-1
📣 Second Presidential Symposium #ESMO26 KRASCENDO-1: Divarasib vs Sotorasib/Adagrasib in 1-3L #KRASG12C #NSCLC 📌 PFS 9.8 vs 5.7m HR 0.58 📌 OS 17.7 vs 12m HR 0.56 ☣️ Diarrhea (66%), N/V (53/39%) @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽 https://t.co/M21g3ISLPv
Oriol Mirallas MD on DeLLphi-305
🔥 Presidential Symposium I #ESMO26 🗣️ @sands_jacob @DanaFarber DeLLphi-305 trial evaluating tarlatamab + durva vs durva as 1LM therapy for ES-SCLC. ✔️ mOS 21.1 vs 12.7m HR 0.42 ✔️ mPFS 7.4 vs 1.9m HR 0.34 ✔️ ORR 26.4 vs 4.1% ☣️ 46.8 vs 40.6% grade 3 or higher @OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol 👇🏽👇🏽
Oriol Mirallas MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#AACR26 New frontiers in oncology 🚀 📌 Elisrasib 2/3L #NSCLC #KRASG12C 🗣️@cbcbc1971 ✔️ ORR 59.5% 2L naive ✔️ ORR 32.3% 3L refractari 🎯 KRASampl ORR 60% 🎯 STK11/KEAP1mut ORR 55 vs 71% 😀 New player #KRASG12C 🚀 Going to 1L in comb CT+IO 🗣️By @DocSacher @OncoAlert @AACR https://t.co/SOZdRu2Sr8
#AACR26 🎯 Mechanisms of resistance in #KRAS inhibitors 🗣️ @kevansf @UCSF 📌 KRASG12Ci and #immunotherapy 📌 In mice with KRASG12C and KRASG12D tumor clones, the combination of #KRASG12Ci and #PD1 had complete responses in ~50% of cases 🤯 🚀 #KRAS space is 🔥 @OncoAlert https://t.co/z2lZ1EqLQ4
#AACR26 New frontiers in oncology 🚀 📌 Zoldonrasib (KRASG12D-ON) #NSCLC #KRASG12D 🗣️Dr. Reiss @ucdavis ✔️ ORR 52% ✔️ DCR 93%, mPFS 11.1m, OS NR ☣️ N/V 43%, diarrhea 30% 😀 New player #KRASG12D @RevMedicines 🗣️By @danieltanmd 👉🏼 Puts into context very nicely @OncoAlert @AACR https://t.co/nmeftCRPVx
#AACR26 💥 Dual Payload #ADC by @AstraZeneca 📌 MMAE DAR 2 + TOPI DAR 8 against #CD30 📌 nnAA 🚀 Increased potency 🐁 👉🏼 New and more potent #ADC being developed and hopefully soon in the #phaseI trials #oncology @AACR @OncoAlert https://t.co/ruUSMdOQSQ
#AACR26 🎯 Exploiting #YAP #TEAD to overcome resistance to #target 💊 🗣️ @SilvioGutkind @UCSDCancerCTO 📌 LXS-196: Darovasertib #PKC #PKN +DATA in #uveal melanoma ➕ #VT3989 increased efficacy in #mice 📌 RAF-MEKi + FAKi #melanoma 📌 #HNSCC PS1 and #VT3989 @OncoAlert https://t.co/jg1KYdIa6Z